RxDoctor Payments Data

David Nesser, MD

Nephrology · Dallas, TXNPI 1376514208

Payments from drug & device makers

$2,454in general payments, 2019–2025

Across 115 payments — averaging $21.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$1K
  • Merck$472
  • Novo Nordisk$227
  • Novartis$85
  • Fresenius USA Marketing, Inc.$81
  • Eurofins Viracor, LLC$69
  • plus $426 from 16 others

What the payments were for

  • Food & beverage$2,39998%
  • Education$10%
  • Entertainment$542%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,454 in reported general payments places this provider in the 55th percentile of 1,070 nephrology providers in Texas.

See all nephrology providers in Texas

Medicare billing

Part B allowed, 2024
$241,966
Medicare patients
581
Services billed
18,561

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban86$66,473
Cinacalcet Hcl122$29,623
Tresiba Flextouch U-100Insulin Degludec48$26,954
FarxigaDapagliflozin Propanediol30$23,136
OzempicSemaglutide16$17,931
LinzessLinaclotide31$16,751
Tacrolimus97$16,515
LokelmaSodium Zirconium Cyclosilicate20$14,163
Nifedipine ErNifedipine436$12,620
VascepaIcosapent Ethyl15$10,789
Repatha SyringeEvolocumab13$10,641
Tresiba Flextouch U-200Insulin Degludec14$10,585
Novolog FlexpenInsulin Aspart52$10,299
TradjentaLinagliptin12$10,003
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog15$9,665

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$66,47386 claims
Boehringer IngelheimTradjenta, Jardiance$40$18,60225 claims
Novo NordiskOzempic$227$17,93116 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 55th percentile of 1,070 nephrology providers in Texas.

Other nephrology in Dallas

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →